HomeNewsTrendsFeaturesPhygital-meets-retail in post-COVID world as luxury retailers struggle to redefine experience

Phygital-meets-retail in post-COVID world as luxury retailers struggle to redefine experience

Dealing with fragmented opening of cities and random shutdowns, retail stores and malls are struggling to draw in footfalls, motivating retailers and owners to evolve solutions such as personal shoppers and curbside pickups.

August 20, 2020 / 16:14 IST
Story continues below Advertisement

Ensemble's executive director Tina Tahiliani Parekh doesn’t remember the last time the store’s crisp concrete-meets-marble interiors were bereft of customers. While there have been a few by-appointment customers, the walk-ins and the vibrancy are missing from one of India’s oldest luxury fashion store.

Story continues below Advertisement

Much like Ensemble, retailers are struggling to make sense of the debilitating effect of lockdowns on the once buzzing retail landscape. The constant ‘open today, shut tomorrow’ situation has sent luxury and premium retail into a tailspin.

Most stores have put in place the basic parameters: not more than two or three staff in the store and a restriction on the number of customers coming in. Yet, while some brands continue to bank on online sales, others such as Reliance Brands Limited have reported increasing footfalls, ranging from 25 -45 percent and retail business of up to 65 percent.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show